Brainin Robert Lawrence 4

What Happened
Robert Lawrence Brainin, a director of Champions Oncology (CSBR), was granted four separate option awards (derivative acquisitions) between Nov 5, 2021 and Nov 12, 2024. The awards total 66,131 options with an aggregate reported value of $410,845. Each grant lists an exercise price and the reported dollar value for the award:

• 11/05/2021: 9,901 options @ $10.10 — $100,000
• 11/01/2022: 14,130 options @ $7.00 — $98,910
• 11/03/2023: 19,070 options @ $5.51 — $105,076
• 11/12/2024: 23,030 options @ $4.64 — $106,859

These are option grants (awards) rather than open-market purchases or sales. Grants are a common form of director compensation; they become exercisable over the vesting schedule noted below.

Key Details

• Transaction dates and terms: see list above (dates, option counts, exercise prices, reported values).
• Shares/options received: 66,131 options in total.
• Shares owned after transaction: Not specified in the provided filing details.
• Vesting: Each grant vests over a 12‑month period in four installments:
  • 11/05/2021 grant vesting on 11/5/2021, 2/5/2022, 5/5/2022, 8/5/2022 (F1)
  • 11/01/2022 grant vesting on 11/1/2022, 2/1/2023, 5/1/2023, 8/1/2023 (F2)
  • 11/03/2023 grant vesting on 11/3/2023, 2/3/2024, 5/3/2024, 8/3/2024 (F3)
  • 11/12/2024 grant vesting on 11/12/2024, 2/12/2025, 5/12/2025, 8/12/2025 (F4)
• Filing timeliness: The report lists a period of report starting 2021-11-05 but was filed on 2026-01-30 — this is a late filing and may reduce the timeliness/usefulness of the disclosure.

Context

• These entries are derivative awards (options). The filing reports grants and vesting schedules; it does not report exercises or any immediate sale of underlying shares. If the options are later exercised, they would convert into common shares (subject to vesting and any exercise/payment).
• Option grants are commonly used for director compensation and do not by themselves indicate immediate buying or selling sentiment. The late filing date, however, means investors received the disclosure significantly after the grant dates.